Company Overview of Receptos, Inc.
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...
3033 Science Park Road
San Diego, CA 92121
Founded in 2008
Key Executives for Receptos, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $534.4K
Co-Founder and Chief Technology Officer
Total Annual Compensation: $317.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $317.0K
Chief Financial Officer
Total Annual Compensation: $386.8K
Chief Medical officer
Total Annual Compensation: $437.8K
Compensation as of Fiscal Year 2014.
Receptos, Inc. Key Developments
Receptos, Inc. Announces Results of the Phase 2 Touchstone Trial - Report
Jul 22 15
Receptos, Inc. reported positive results for the maintenance period of TOUCHSTONE, the Phase 2 trial of ozanimod (formerly RPC1063) in ulcerative colitis (UC). The results showed that the study has met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment. Assessment Of Ozanimod Versus Placebo In Details- The aforesaid study evaluated the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of ozanimod versus placebo. This randomized, double-blind, placebo-controlled trial was conducted in 199 patients with moderately-to-severely active UC across 57 sites in 13 countries. Receptos informed that the trial met its primary efficacy and all secondary endpoints for patients with 1 mg dose after 8 weeks of treatment in the induction period. The 103 patients, who achieved clinical response in the maintenance period at the eight week, continued with treatment for 24 more weeks. At week 32, all secondary end-points were positive and statistically significant for the 1 mg dose. The secondary endpoints at week 32 included clinical response, change in the industry standard Mayo score and mucosal improvement on endoscopy. Further, the proportion of patients in clinical remission at week 32 was statistically significant in favor of both the 1 mg group and the 0.5 mg group (p < 0.05) compared to placebo. Plans to start Phase 3Trial - In 2015, the Company plans to go ahead with a Phase 3 program to confirm the findings of Phase 2. The phase 3 trial would be conducted in patients with moderately-to-severely active UC. Furthermore, these results continue to suggest the potential for ozanimod to be used in the treatment of a related inflammatory bowel disease called Crohn's. The Company stated that it would be initiating a Phase 2 study of ozanimod for the treatment of Crohn's disease in 2015.
Celgene Corporation, Receptos, Inc. - M&A Call
Jul 14 15
To discuss the strategic acquisition of Receptos
Receptos, Inc.(NasdaqGS:RCPT) added to Russell 1000 Index
Jun 30 15
Receptos, Inc. has been added to Russell 1000 Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 14, 2015
Most Searched Private Companies
Sponsored Financial Commentaries